Cat Allergy Clinical Trial
Official title:
A Dose-Escalating Phase 0 Study to Evaluate the Safety and Local Cutaneous Reactivity of Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD) in Cat-allergic Healthy Volunteers
The purpose of this trial is to show that Intradermal Human Fcγ1-Fel d1 fusion protein (GFD) is able to block the skin reaction to cat allergen in cat allergic subjects compared to the skin reaction to cat allergen alone. This research project is also testing the safety and tolerability of this new, experimental treatment, compared to the current treatment of cat allergen alone.
Status | Terminated |
Enrollment | 4 |
Est. completion date | April 2011 |
Est. primary completion date | April 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - History of allergic reactivity to cats as expressed by allergic rhinitis - Radioallergosorbent test (RAST test) for cat-specific IgE with RAST rating of 2 (0.70-3.49 KU/L IgE) documented within the past year or at screening - Standardized cat hair allergenic extract (CAT), 10,000 BAL/mL (ALK-Abello) elicits a wheal 5 mm or greater than the diluent control (Saline Albumin with Phenol [HSA], ALK-Abello) with surrounding erythema on testing using a standardized epicutaneous delivery device (Stallergenes Prick Lancet, 1 mm tip) - Histamine (Histatrol 1mg/mL, ALK-Abello) reactivity of 5 mm or greater reactivity than the diluent control with surrounding erythema on epicutaneous testing using a standardized epicutaneous delivery device - Able and willing to discontinue any anti-histamine use for 5 days prior to entry into protocol and throughout the protocol participation - Baseline spirometry (FEV1, FVC FEF25-75) with FEV1 >=80% predicted and other values within the normal range - Ability to give written informed consent Exclusion Criteria: - Diluent control (Saline Albumin with Phenol [HSA], ALK-Abello) elicits wheal >= 3 mm on epicutaneous testing using a standardized epicutaneous delivery device - Pregnant females as determined by a positive serum or urine hCG test - Lactating females - Ever having received allergen immunotherapy (e.g., -subcutaneous allergen [SCIT] or -sublingual [SLIT]) - Systemic steroids in the past 3 months - Severe systemic reactivity on exposure to cats (e.g., laryngeal or angioedema, fainting, pallor, bradycardia, hypotension, bronchospasm, asthma, or generalized urticaria) - A clinical history of asthma - Underlying heart, liver, kidney lung, or other medical condition (acute infections, immune diseases, current substance abuse) such that the person would be at a clearly increased risk for a poor outcome should a generalized allergic reaction occur - Use of systemic beta-blocking or ACE-inhibiting agents within the past 3 weeks - Use of tri-cyclic antidepressants within the past 3 weeks - Subjects receiving therapy with any agents known or likely to interact with adrenaline (e.g., beta blockers, ACE-Inhibitors, tri-cyclic antidepressants, or other) - Current use or use of omalizumab (Xolair) within past 6 months - Subjects with any extensive skin disorder (atopic dermatitis) that would make skin testing or proper interpretation impractical - Mental impairment, limiting the ability to comply with study requirements - Participation in a clinical trial and receipt of an investigational product within 30 days, 5 half-lives or twice the duration of the biochemical effect of the investigational product (whichever is longer) prior to dosing in the current study |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Alfred Hospital and Monash University | Melbourne | Victoria |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN), Tunitas Therapeutics, Inc. |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in the Doses of GFD and CAT Required to Elicit a Cutaneous Reaction Demonstrated by a Wheal Greater Than or Equal to 10 mm With Surrounding Erythema | Difference in the doses of human Fcgamma1-Fel d1 (cat allergen) fusion protein (GFD) and standardized cat hair allergenic extract (CAT) required to elicit a wheal = 10 mm with surrounding erythema. | up to 3 hours after the last injection of GFD | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02959073 -
Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients
|
N/A | |
Completed |
NCT00987909 -
Exposure Chamber Trial With Cat Immunotherapy
|
Phase 2 | |
Completed |
NCT01383590 -
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis
|
Phase 1 | |
Completed |
NCT01383603 -
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
|
Phase 1 | |
Completed |
NCT01003301 -
The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
|
Phase 2 | |
Completed |
NCT02311413 -
A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy
|
Phase 2 | |
Completed |
NCT02237196 -
Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy
|
Phase 1/Phase 2 | |
Completed |
NCT02399579 -
Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients
|
N/A | |
Completed |
NCT00867906 -
Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma
|
Phase 2 | |
Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
Completed |
NCT01033344 -
Cat-PAD Exposure Chamber Study
|
Phase 2 | |
Completed |
NCT00685711 -
Safety of Cat-PAD in Cat Allergic Subjects
|
Phase 1/Phase 2 | |
Completed |
NCT02040844 -
Phase III Cat-PAD Follow-on Study
|
Phase 3 | |
Completed |
NCT01604018 -
An Optional Two Year Follow Up Study to Study CP005A
|
N/A | |
Completed |
NCT01272323 -
Cat-PAD Follow on Study
|
N/A | |
Completed |
NCT03838731 -
Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge
|
Phase 2 | |
Completed |
NCT00729508 -
Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects
|
Phase 2 | |
Recruiting |
NCT05331170 -
Viral Mucosal Reprogramming
|
Phase 2 |